Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 13/20 | 0.55 |
| ▸ | ACHE | P22303 | 12/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30382732 | 1.00 | PTPN1 (0.56) | PTPN1BCHEACHEPPARABRAF | |
| SCHEMBL31463102 | 0.88 | BCHE (0.55) | BCHEACHEPPARABRAFKDR | |
| SCHEMBL29014275 | 0.88 | BCHE (0.55) | BCHEACHEPPARABRAFKDR | |
| SCHEMBL29014198 | 0.88 | BCHE (0.57) | BCHEACHEBRAFKDR | |
| SCHEMBL25284515 | 0.88 | ABCG2 (0.57) | PTPN1BCHEACHEPPARAMAOA | |
| SCHEMBL30384245 | 0.88 | ABCG2 (0.57) | PTPN1BCHEACHEPPARAMAOA | |
| SCHEMBL25200421 | 0.87 | KMT2A (0.61) | PTPN1BCHEACHEBRAFKDR | |
| SCHEMBL25193715 | 0.86 | BCHE (0.70) | BCHEACHEPPARAMAOAMAOB | |
| SCHEMBL25234108 | 0.86 | MAOA (0.58) | BCHEACHEPPARAMAOAMAOB | |
| SCHEMBL25243102 | 0.86 | MAOB (0.62) | BCHEACHEPPARAMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | PTPN1 1308/4885BCHE 588/4885ACHE 806/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | PTPN1 1520/4885BCHE 465/4885ACHE 656/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | PTPN1 1520/4885BCHE 465/4885ACHE 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.